ALIM Alimera Sciences, Inc.

1.39
+0  (1%)
Previous Close 1.37
Open 1.38
Price To book 0.00
Market Cap 90.16M
Shares 64,862,000
Volume 507,726
Short Ratio 1.07
Av. Daily Volume 660,313

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
Iluvien
Diabetic macular edema

Latest News

  1. ETFs with exposure to Alimera Sciences, Inc. : April 20, 2017
  2. ETFs with exposure to Alimera Sciences, Inc. : March 27, 2017
  3. Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  4. Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  5. Alimera Sciences, Inc. (ALIM) Looks Good: Stock Up 12.8%
  6. Alimera Sciences Signs Agreement for Exclusive Distributor of ILUVIEN® in Spain
  7. Alimera Sciences to Present at the 29th Annual ROTH Conference
  8. Alimera Sciences to Present at the 37th Annual Cowen Health Care Conference
  9. Edited Transcript of ALIM earnings conference call or presentation 2-Mar-17 3:00pm GMT
  10. Alimera Sciences reports 4Q loss
  11. Alimera Sciences Reports Record Fourth Quarter and Full Year 2016 Financial Results
  12. Alimera Sciences to Report Fourth Quarter 2016 Financial Results on March 1, 2017
  13. Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien® in Canada
  14. Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien(R) in Canada
  15. Alimera Sciences Announces the Reimbursement of ILUVIEN® in Italy
  16. ETFs with exposure to Alimera Sciences, Inc. : January 11, 2017
  17. Is Alimera Sciences Inc (ALIM) A Good Stock To Buy?
  18. ETFs with exposure to Alimera Sciences, Inc. : December 16, 2016